1174009-31-4

Upstream product

• 7311-93-5 3-(piperidin-1-ylsulfonyl)benzoic acid 
• 4025-64-3 3-Carboxybenzenesulfonyl chloride 
• 110-89-4 piperidine 

Downstream Products

• 872548-22-6 3-(piperidin-1-ylsulfonyl)benzaldehyde 
• 1192233-45-6 1-{[3-(chloromethyl)phenyl]sulfonyl}piperidine 
• 1192233-50-3 ethyl (2E)-3-[3-(piperidin-1-ylsulfonyl)phenyl]acrylate 
• 1192233-51-4 (2E)-3-[3-(piperidin-1-ylsulfonyl)phenyl]acrylic acid 
• 1192233-47-8 [3-(Piperidin-1-ylsulfonyl)phenyl]acetonitrile 
• 1192233-46-7 C₁₂H₁₆N₄O₂S 
• 848813-81-0 C₁₂H₁₈N₂O₂S 
• 1192233-48-9 C₁₃H₁₇NO₄S 
• 1192274-14-8 C₁₃H₂₀N₂O₂S 

Relevant academic research and scientific papers

FLT3 RECEPTOR ANTAGONISTS

The invention pertains to novel FLT3receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.

LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT

[Problem] To provide compounds useful as preventives or remedies for circular system disorders, nervous system disorders, metabolic disorders, reproduction system disorders, digestive system disorders, neoplasm, infectious diseases, etc., or as herbicides. [Means for Solution] A long-chain fatty acyl elongase inhibitor comprising, as the active ingredient thereof, a compound or a pharmaceutically-active salt thereof of a formula (I): [wherein W represents a hydrogen atom, a C1-6 alkyl, etc.; X represents an aryl, a heteroaryl, etc.; n indicates 0 or 1; Z represents a hydrogen atom, a C1-6 alkyl, etc.; A1, A2, A3 and A4 each independently represent CH or N].

Compounds Having CRTH2 Antagonist Activity

Compounds of general formula (I) wherein W is chloro or fluoro; Z is a group SO2R1; wherein R1 is —C3-C8 cycloalkyl or heterocyclyl optionally substituted with one or more substituents chosen from hal

COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY

Compounds of general formula (I): wherein W is chloro or fluoro; Z is a group SO2R1; wherein R1 is -C3-C8 cycloalkyl or heterocyclyl optionally substituted with one or more substituents chosen from halo, -CN, -C1-C6 alkyl, -SOR3, -SO2R3, -SO2N(R2)2, -N(R2)2, -NR2C(O)R3, -CO2R2, -CONR2R3, -NO2, -OR2, -SR2, -O(CH2)POR2, and - O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, -Ci-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.